Kidney transplant patients test drug switch to prevent organ rejection
NCT ID NCT05193565
Summary
This study compares two different anti-rejection medications (RaparoBell® and My-Rept®) for kidney transplant patients who are already taking standard maintenance therapy. Researchers want to see which drug works better and is safer when patients switch to it. The trial involves 206 patients who received a kidney transplant 1-10 years ago and will track them for 24 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, South Korea
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.